TrialInternational journal of clinical oncology2016

Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).

Chu Matsuda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.